ImmuneOnco secures FDA IND clearance for Phase Ib/II study of dual-targeting antibody IMM0306 in systemic lupus erythematosus

Bulletin Express

Aug 21

Hong Kong-listed ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B, 01541) reported that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for IMM0306, authorising a Phase Ib/II clinical trial in systemic lupus erythematosus (SLE).

IMM0306 is a bispecific molecule that simultaneously targets CD47 and CD20. By blocking the CD47-SIRPα “don’t eat me” signal and enhancing Fc-mediated activation of macrophages and natural killer cells, the agent is designed to eliminate malignant B-cells while limiting toxicity. According to the company, IMM0306 is the first CD47/CD20 dual-targeting bispecific antibody to enter clinical development worldwide, and ImmuneOnco retains full global intellectual property and commercial rights.

The announcement, dated 21 August 2026, is voluntary under Hong Kong listing rules. The company reiterates that successful development or commercialisation of IMM0306 is not assured and advises shareholders and potential investors to exercise caution when dealing in its shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1119750546"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1119750546\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1119750546?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-21 20:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119750546","market":"us","top_or_hot":-1,"title":"ImmuneOnco secures FDA IND clearance for Phase Ib/II study of dual-targeting antibody IMM0306 in systemic lupus erythematosus","media":"Bulletin Express","content":"<p>Hong Kong-listed ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B, 01541) reported that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for IMM0306, authorising a Phase Ib/II clinical trial in systemic lupus erythematosus (SLE).</p>\n<p>IMM0306 is a bispecific molecule that simultaneously targets CD47 and CD20. By blocking the CD47-SIRPα “don’t eat me” signal and enhancing Fc-mediated activation of macrophages and natural killer cells, the agent is designed to eliminate malignant B-cells while limiting toxicity. According to the company, IMM0306 is the first CD47/CD20 dual-targeting bispecific antibody to enter clinical development worldwide, and ImmuneOnco retains full global intellectual property and commercial rights.</p>\n<p>The announcement, dated 21 August 2026, is voluntary under Hong Kong listing rules. The company reiterates that successful development or commercialisation of IMM0306 is not assured and advises shareholders and potential investors to exercise caution when dealing in its shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmuneOnco secures FDA IND clearance for Phase Ib/II study of dual-targeting antibody IMM0306 in systemic lupus erythematosus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuneOnco secures FDA IND clearance for Phase Ib/II study of dual-targeting antibody IMM0306 in systemic lupus erythematosus\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-21 20:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong-listed ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B, 01541) reported that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for IMM0306, authorising a Phase Ib/II clinical trial in systemic lupus erythematosus (SLE).</p>\n<p>IMM0306 is a bispecific molecule that simultaneously targets CD47 and CD20. By blocking the CD47-SIRPα “don’t eat me” signal and enhancing Fc-mediated activation of macrophages and natural killer cells, the agent is designed to eliminate malignant B-cells while limiting toxicity. According to the company, IMM0306 is the first CD47/CD20 dual-targeting bispecific antibody to enter clinical development worldwide, and ImmuneOnco retains full global intellectual property and commercial rights.</p>\n<p>The announcement, dated 21 August 2026, is voluntary under Hong Kong listing rules. The company reiterates that successful development or commercialisation of IMM0306 is not assured and advises shareholders and potential investors to exercise caution when dealing in its shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"","article_id":"1119750546","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119750546","pubTimestamp":1787316325,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong-listed ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B, 01541) reported that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B"},"translate_title":"ImmuneOnco获得FDA IND批准，用于双靶向抗体IMM0306治疗系统性红斑狼疮的Ib/II期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1},"content_text":"Hong Kong-listed ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B, 01541) reported that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for IMM0306, authorising a Phase Ib/II clinical trial in systemic lupus erythematosus (SLE).\nIMM0306 is a bispecific molecule that simultaneously targets CD47 and CD20. By blocking the CD47-SIRPα “don’t eat me” signal and enhancing Fc-mediated activation of macrophages and natural killer cells, the agent is designed to eliminate malignant B-cells while limiting toxicity. According to the company, IMM0306 is the first CD47/CD20 dual-targeting bispecific antibody to enter clinical development worldwide, and ImmuneOnco retains full global intellectual property and commercial rights.\nThe announcement, dated 21 August 2026, is voluntary under Hong Kong listing rules. The company reiterates that successful development or commercialisation of IMM0306 is not assured and advises shareholders and potential investors to exercise caution when dealing in its shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}